Treatment of insomia: A review and update

Rafia S. Rasu, Rajesh Balkrishnan, Rahul A. Shenolikar, Milap C. Nahata

Research output: Contribution to journalReview article

Abstract

The purpose of this review is to provide an update on the treatment options available and their usage and outcomes in the treatment of insomnia in the USA. Both pharmacotherapy and behavioral therapy are recommended in the physician guidelines for insomnia management. Although pharmacotherapy can produce a rapid pharmacologic effect, for long-term effectiveness, behavioral therapy can be considered for chronic primary insomniac patients. The cost of behavioral therapy is a notable barrier to its prescription for patients with sleep difficulties. Increased utilization of both behavioral- and pharmacotherapy may reduce insomnia-related healthcare costs and increase health-related quality of life. Further research should focus on the role of these therapies in outcomes of insomnia management.

Original languageEnglish
Pages (from-to)733-740
Number of pages8
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume5
Issue number6
DOIs
StatePublished - 1 Dec 2005

Fingerprint

Sleep Initiation and Maintenance Disorders
Drug Therapy
Therapeutics
Health Care Costs
Prescriptions
Sleep
Quality of Life
Guidelines
Physicians
Costs and Cost Analysis
Research

Keywords

  • Behavioral therapy
  • Health outcomes
  • Health-related quality of life
  • Insomia
  • Pharmacotherapy

Cite this

Rasu, Rafia S. ; Balkrishnan, Rajesh ; Shenolikar, Rahul A. ; Nahata, Milap C. / Treatment of insomia : A review and update. In: Expert Review of Pharmacoeconomics and Outcomes Research. 2005 ; Vol. 5, No. 6. pp. 733-740.
@article{fb68a3e051bf425091ae3d8577caaff0,
title = "Treatment of insomia: A review and update",
abstract = "The purpose of this review is to provide an update on the treatment options available and their usage and outcomes in the treatment of insomnia in the USA. Both pharmacotherapy and behavioral therapy are recommended in the physician guidelines for insomnia management. Although pharmacotherapy can produce a rapid pharmacologic effect, for long-term effectiveness, behavioral therapy can be considered for chronic primary insomniac patients. The cost of behavioral therapy is a notable barrier to its prescription for patients with sleep difficulties. Increased utilization of both behavioral- and pharmacotherapy may reduce insomnia-related healthcare costs and increase health-related quality of life. Further research should focus on the role of these therapies in outcomes of insomnia management.",
keywords = "Behavioral therapy, Health outcomes, Health-related quality of life, Insomia, Pharmacotherapy",
author = "Rasu, {Rafia S.} and Rajesh Balkrishnan and Shenolikar, {Rahul A.} and Nahata, {Milap C.}",
year = "2005",
month = "12",
day = "1",
doi = "10.1586/14737167.5.6.733",
language = "English",
volume = "5",
pages = "733--740",
journal = "Expert Review of Pharmacoeconomics and Outcomes Research",
issn = "1473-7167",
publisher = "Taylor and Francis Ltd.",
number = "6",

}

Treatment of insomia : A review and update. / Rasu, Rafia S.; Balkrishnan, Rajesh; Shenolikar, Rahul A.; Nahata, Milap C.

In: Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 5, No. 6, 01.12.2005, p. 733-740.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Treatment of insomia

T2 - A review and update

AU - Rasu, Rafia S.

AU - Balkrishnan, Rajesh

AU - Shenolikar, Rahul A.

AU - Nahata, Milap C.

PY - 2005/12/1

Y1 - 2005/12/1

N2 - The purpose of this review is to provide an update on the treatment options available and their usage and outcomes in the treatment of insomnia in the USA. Both pharmacotherapy and behavioral therapy are recommended in the physician guidelines for insomnia management. Although pharmacotherapy can produce a rapid pharmacologic effect, for long-term effectiveness, behavioral therapy can be considered for chronic primary insomniac patients. The cost of behavioral therapy is a notable barrier to its prescription for patients with sleep difficulties. Increased utilization of both behavioral- and pharmacotherapy may reduce insomnia-related healthcare costs and increase health-related quality of life. Further research should focus on the role of these therapies in outcomes of insomnia management.

AB - The purpose of this review is to provide an update on the treatment options available and their usage and outcomes in the treatment of insomnia in the USA. Both pharmacotherapy and behavioral therapy are recommended in the physician guidelines for insomnia management. Although pharmacotherapy can produce a rapid pharmacologic effect, for long-term effectiveness, behavioral therapy can be considered for chronic primary insomniac patients. The cost of behavioral therapy is a notable barrier to its prescription for patients with sleep difficulties. Increased utilization of both behavioral- and pharmacotherapy may reduce insomnia-related healthcare costs and increase health-related quality of life. Further research should focus on the role of these therapies in outcomes of insomnia management.

KW - Behavioral therapy

KW - Health outcomes

KW - Health-related quality of life

KW - Insomia

KW - Pharmacotherapy

UR - http://www.scopus.com/inward/record.url?scp=30344474909&partnerID=8YFLogxK

U2 - 10.1586/14737167.5.6.733

DO - 10.1586/14737167.5.6.733

M3 - Review article

C2 - 19807615

AN - SCOPUS:30344474909

VL - 5

SP - 733

EP - 740

JO - Expert Review of Pharmacoeconomics and Outcomes Research

JF - Expert Review of Pharmacoeconomics and Outcomes Research

SN - 1473-7167

IS - 6

ER -